{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:38:37Z","timestamp":1789717117199,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s11940-016-0435-0","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T04:46:51Z","timestamp":1477543611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current Treatment of Multiple System Atrophy"],"prefix":"10.1007","volume":"18","author":[{"given":"Sylvia","family":"Maa\u00df","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"issue":"2\u20133","key":"435_CR1","first-page":"189","volume":"74","author":"S Gilman","year":"1998","unstructured":"Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. J Auton Nerv Syst. 1998;74(2\u20133):189\u201392.","journal-title":"J Auton Nerv Syst"},{"key":"435_CR2","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670\u20136. These are the current diagnostic criteria of MSA.","DOI":"10.1212\/01.wnl.0000324625.00404.15"},{"issue":"2","key":"435_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870120203","volume":"12","author":"GK Wenning","year":"1997","unstructured":"Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133\u201347.","journal-title":"Mov Disord"},{"issue":"15","key":"435_CR4","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/mds.21578","volume":"22","author":"R Constantinescu","year":"2007","unstructured":"Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord. 2007;22(15):2141\u20138.","journal-title":"Mov Disord"},{"issue":"4","key":"435_CR5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/jnnp.68.4.434","volume":"68","author":"GK Wenning","year":"2000","unstructured":"Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson\u2019s disease? J Neurol Neurosurg Psychiatry. 2000;68(4):434\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"435_CR6","doi-asserted-by":"crossref","unstructured":"\u2022 Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, Sawires M, Kollensperger M, et al. Health-related quality of life in multiple system atrophy. Mov Disord. 2006;21:809\u201315. This work identifies the factors which compromise the quality of life of MSA patients.","DOI":"10.1002\/mds.20808"},{"issue":"3","key":"435_CR7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","volume":"12","author":"GK Wenning","year":"2013","unstructured":"\u2022\u2022 Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12(3):264\u201374. This study is of pivotal importance to understand the course of the disease.","journal-title":"Lancet Neurol"},{"issue":"3","key":"435_CR8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","volume":"372","author":"A Fanciulli","year":"2015","unstructured":"\u2022Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372(3):249\u201363. This work provides a well written and comprehensive overview on MSA.","journal-title":"N Engl J Med"},{"issue":"4","key":"435_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1353-8020(97)00022-9","volume":"3","author":"AH Rajrut","year":"1997","unstructured":"Rajrut AH, Uitti RJ, Fenton ME, George D. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 1997;3(4):211\u20134.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"435_CR10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s004150200009","volume":"249","author":"J M\u00fcller","year":"2002","unstructured":"M\u00fcller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol. 2002;249(3):300\u20134.","journal-title":"J Neurol"},{"key":"435_CR11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/mds.1101","volume":"16","author":"S Thobois","year":"2001","unstructured":"Thobois S, Broussolle E, Toureille L, Vial C. Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. Mov Disord. 2001;16:764\u20135.","journal-title":"Mov Disord"},{"issue":"12","key":"435_CR12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1474-4422(09)70288-1","volume":"8","author":"N Stefanova","year":"2009","unstructured":"Stefanova N, B\u00fccke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol. 2009;8(12):1172\u20138.","journal-title":"Lancet Neurol"},{"issue":"1","key":"435_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0002-9343(93)90230-M","volume":"95","author":"J Jankovic","year":"1993","unstructured":"Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38\u201348.","journal-title":"Am J Med"},{"issue":"6","key":"435_CR14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000083721.49847.D7","volume":"108","author":"H Kaufmann","year":"2003","unstructured":"Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724\u20138.","journal-title":"Circulation"},{"issue":"4","key":"435_CR15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02298955","volume":"11","author":"CJ Mathias","year":"2001","unstructured":"Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11(4):235\u201342.","journal-title":"Clin Auton Res"},{"issue":"5","key":"435_CR16","first-page":"61","volume":"113","author":"J Levin","year":"2016","unstructured":"Levin J, Kurz A, Arzberger T, Giese A, H\u00f6glinger GU. The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int. 2016;113(5):61\u20139.","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"435_CR17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0022-5347(17)35246-1","volume":"151","author":"RO Beck","year":"1994","unstructured":"Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol. 1994;151(5):1336\u201341.","journal-title":"J Urol"},{"issue":"3","key":"435_CR18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/jnnp.71.3.371","volume":"71","author":"IF Hussain","year":"2001","unstructured":"Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson\u2019s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71(3):371\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"435_CR19","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/mds.1211","volume":"16","author":"TE Eichhorn","year":"2001","unstructured":"Eichhorn TE, Oertel WH. Macrogol 3350\/electrolyte improves constipation in Parkinson\u2019s disease and multiple system atrophy. Mov Disord. 2001;16(6):1176\u20137.","journal-title":"Mov Disord"},{"issue":"2","key":"435_CR20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mdc3.12025","volume":"1","author":"SM Abbott","year":"2014","unstructured":"Abbott SM, Videnovic A. Sleep disorders in atypical Parkinsonism. Mov Disord Clin Pract. 2014;1(2):89\u201396.","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"435_CR21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/1531-8257(200007)15:4<699::AID-MDS1015>3.0.CO;2-L","volume":"15","author":"MH Silber","year":"2000","unstructured":"Silber MH, Levine S. Stridor and death in multiple system atrophy. Mov Disord. 2000;15(4):699\u2013704.","journal-title":"Mov Disord"},{"issue":"4","key":"435_CR22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1212\/WNL.40.4.677","volume":"40","author":"FE Munschauer","year":"1990","unstructured":"Munschauer FE, Loh L, Bannister R, Newsom-Davis J. Abnormal respiration and sudden death during sleep in multiple system atrophy with autonomic failure. Neurology. 1990;40(4):677\u20139.","journal-title":"Neurology"},{"issue":"10","key":"435_CR23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00415-008-0941-4","volume":"255","author":"T Shimohata","year":"2008","unstructured":"Shimohata T, Ozawa T, Nakayama H, Tomita M, Shinoda H, Nishizawa M. Frequency of nocturnal sudden death in patients with multiple system atrophy. J Neurol. 2008;255(10):1483\u20135.","journal-title":"J Neurol"},{"issue":"9238","key":"435_CR24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(00)02824-5","volume":"356","author":"A Iranzo","year":"2000","unstructured":"Iranzo A, Santamaria J, Tolosa E. Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group. Lancet. 2000;356(9238):1329\u201330.","journal-title":"Lancet"},{"issue":"12","key":"435_CR25","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00702-005-0348-7","volume":"112","author":"I Ghorayeb","year":"2005","unstructured":"Ghorayeb I, Bioulac B, Tison F. Sleep disorders in multiple system atrophy. J Neural Transm. 2005;112(12):1669\u201375.","journal-title":"J Neural Transm"},{"issue":"5","key":"435_CR26","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/01.WNL.0000137043.76383.A4","volume":"63","author":"A Iranzo","year":"2004","unstructured":"Iranzo A, Santamaria J, Tolosa E, Vilaseca I, Valldeoriola F, Mart\u00ed MJ, et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology. 2004;63(5):930\u20132.","journal-title":"Neurology"},{"issue":"19","key":"435_CR27","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1212\/01.wnl.0000260975.74618.d7","volume":"68","author":"K Jin","year":"2007","unstructured":"Jin K, Okabe S, Chida K, Abe N, Kimpara T, Ohnuma A, et al. Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy. Neurology. 2007;68(19):1618\u201321.","journal-title":"Neurology"},{"issue":"12","key":"435_CR28","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1212\/01.wnl.0000307657.51386.fa","volume":"70","author":"MH Silber","year":"2008","unstructured":"Silber MH. Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy. Neurology. 2008;70(12):980. author reply 981\u20132.","journal-title":"Neurology"},{"issue":"7","key":"435_CR29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/mds.20891","volume":"21","author":"F Tison","year":"2006","unstructured":"Tison F, Yekhlef F, Chrysostome V. Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson\u2019s disease. Mov Disord. 2006;21(7):1056\u20137.","journal-title":"Mov Disord"},{"issue":"7","key":"435_CR30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.parkreldis.2006.04.002","volume":"12","author":"E Friess","year":"2006","unstructured":"Friess E, Kuempfel T, Modell S, Winkelmann J, Holsboer F, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord. 2006;12(7):432\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 1","key":"435_CR31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","volume":"132","author":"G Bensimon","year":"2009","unstructured":"Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156\u201371.","journal-title":"Brain"},{"issue":"8","key":"435_CR32","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.21501","volume":"22","author":"B Holmberg","year":"2007","unstructured":"Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn NP, Mathias C, et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord. 2007;22(8):1138\u201344.","journal-title":"Mov Disord"},{"issue":"1","key":"435_CR33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/mds.24885","volume":"27","author":"W Poewe","year":"2012","unstructured":"Poewe W, Barone P, Gliadi N, Gilman S, Low PA, Sampaio C, et al. A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype. Movement Disorders. 2012;27(1):S1\u2013S523.","journal-title":"Movement Disorders"},{"issue":"1","key":"435_CR34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mds.22732","volume":"25","author":"R Dodel","year":"2010","unstructured":"Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25(1):97\u2013107.","journal-title":"Mov Disord"},{"issue":"3","key":"435_CR35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","volume":"13","author":"PA Low","year":"2014","unstructured":"Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(3):268\u201375.","journal-title":"Lancet Neurol"},{"issue":"1","key":"435_CR36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","volume":"72","author":"PH Lee","year":"2012","unstructured":"\u2022 Lee PH, Lee JE, Kim HS, Song SK, Lee HS, Nam HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012;72(1):32\u201340. The only trial so far to show disease modification in MSA. Confirmation is pending.","journal-title":"Ann Neurol"},{"issue":"5","key":"435_CR37","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.clpt.6100454","volume":"83","author":"N Quinn","year":"2008","unstructured":"Quinn N, Barker RA, Wenning GK. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Clin Pharmacol Ther. 2008;83(5):663\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"435_CR38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00702-016-1507-8","volume":"123","author":"J Levin","year":"2016","unstructured":"Levin J, Maa\u00df S, Schuberth M, Respondek G, Paul F, Mansmann U, et al. The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transm (Vienna). 2016;123(4):439\u201345.","journal-title":"J Neural Transm (Vienna)"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0435-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-016-0435-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0435-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T02:33:40Z","timestamp":1568514820000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-016-0435-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1007\/s11940-016-0435-0","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]},"article-number":"51"}}